King's Health Economics (KHE), Institute of Psychiatry, Psychology & Neuroscience at King's College London, London, United Kingdom.
Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom.
PLoS One. 2023 Sep 14;18(9):e0291366. doi: 10.1371/journal.pone.0291366. eCollection 2023.
Whole disease models (WDM) are large-scale, system-level models which can evaluate multiple decision questions across an entire care pathway. Whilst this type of model can offer several advantages as a platform for undertaking economic analyses, the availability and quality of existing WDMs is unknown.
This systematic review aimed to identify existing WDMs to explore which disease areas they cover, to critically assess the quality of these models and provide recommendations for future research.
An electronic search was performed on multiple databases (MEDLINE, EMBASE, the NHS Economic Evaluation Database and the Health Technology Assessment database) on 23rd July 2023. Two independent reviewers selected studies for inclusion. Study quality was assessed using the National Institute for Health and Care Excellence (NICE) appraisal checklist for economic evaluations. Model characteristics were descriptively summarised.
Forty-four WDMs were identified, of which thirty-two were developed after 2010. The main disease areas covered by existing WDMs are heart disease, cancer, acquired immune deficiency syndrome and metabolic disease. The quality of included WDMs is generally low. Common limitations included failure to consider the harms and costs of adverse events (AEs) of interventions, lack of probabilistic sensitivity analysis (PSA) and poor reporting.
There has been an increase in the number of WDMs since 2010. However, their quality is generally low which means they may require significant modification before they could be re-used, such as modelling AEs of interventions and incorporation of PSA. Sufficient details of the WDMs need to be reported to allow future reuse/adaptation.
全疾病模型(WDM)是一种大规模的、系统水平的模型,可以评估整个治疗路径中的多个决策问题。虽然这种类型的模型作为进行经济分析的平台具有多个优势,但现有的 WDM 的可用性和质量是未知的。
本系统评价旨在识别现有的 WDM,以探索它们涵盖的疾病领域,批判性地评估这些模型的质量,并为未来的研究提供建议。
于 2023 年 7 月 23 日在多个数据库(MEDLINE、EMBASE、NHS 经济评价数据库和卫生技术评估数据库)上进行了电子检索。两名独立的审查员选择纳入的研究。使用英国国家卫生与临床优化研究所(NICE)的经济评估评估清单评估研究质量。模型特征进行了描述性总结。
确定了 44 个 WDM,其中 32 个是在 2010 年后开发的。现有 WDM 涵盖的主要疾病领域是心脏病、癌症、获得性免疫缺陷综合征和代谢疾病。纳入的 WDM 质量普遍较低。常见的局限性包括未能考虑干预措施的不良事件(AE)的危害和成本、缺乏概率敏感性分析(PSA)和报告不良。
自 2010 年以来,WDM 的数量有所增加。然而,它们的质量普遍较低,这意味着在重新使用之前可能需要进行重大修改,例如对干预措施的 AE 进行建模和纳入 PSA。需要充分报告 WDM 的详细信息,以允许未来的重复使用/改编。